Telix to participate in UBS Global Biopharma Conference. 2026-11-11 15:00 1 MELBOURNE, Australia and INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK). Dr. Christian Behrenbruch, Managing Director and Group CEO, and Mr. Richard Valeix, CEO Therapeutics, will take part in a fireside chat on Tuesday, November 17, 2026 at 9:20 a.m. GMT (4:20 a.m. EST, 8:20 p.m. AEDT). The session will be webcast live, and accessible through Telix's Investor Relations website. About Telix Pharmaceuticals Limited Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Telix's commercial franchise is anchored by its precision diagnostics portfolio: Illuccix(R)(kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix(R)(kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara(R)(floretyrosine F 18) approved by the FDA for glioma imaging. The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 ([177] Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan [131] I) in recurrent glioblastoma, and TLX250-Tx (lutetium ([177] Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook. | Investor Relations Annie Kasparian [email protected] Charlene Jaw [email protected] | Media Eliza Schleifstein 917.763.8106 (Mobile) [email protected] | Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with its risk factors, as disclosed in its most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC, or on its website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the(R) or(TM) symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

Telix joins Thera4Care with TLX400-Tx to accelerate translation of next generation fap-targeting theranostics. medical research November 05, 2026 * Thera4Care is an initiative aimed at establishing an integrated theranostics ecosystem to broaden patient access in Europe * Telix's fibroblast activation protein (FAP) targeting therapy candidate (TLX400-Tx) has been selected for evaluation with terbium-161 based on clinical potential and external scientific interest * Data generated through the collaboration are expected to help inform future development directions for this promising target. MELBOURNE, Australia and INDIANAPOLIS, Nov. 5, 2026 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has joined Thera4Care, an initiative aimed at establishing an integrated, collaborative ecosystem for theranostics (therapeutic and diagnostic radiopharmaceuticals) to broaden patient access in Europe. The project includes 27 partners from top European academic centers, healthcare providers, industry stakeholders, and patient advocacy groups. Within its vision of making personalized theranostics an integral part of cancer care across Europe and beyond, one goal of Thera4Care is to evaluate novel approaches to targeting metastatic disease in clinical settings. The consortium has selected Telix's FAP-targeting dimer (DOTAGA.Glu.(FAPi)[2]), which has been validated in several clinical studies already[[1]], for clinical testing with terbium-161 ([161] Tb). Unlike lutetium-177 ([177] Lu), [161] Tb emits not only beta particles but also Auger electrons over extremely short distances, making it uniquely suited to destroying micro-metastatic disease, while sparing surrounding healthy tissue. As part of the collaboration, a Phase 1 clinical trial will explore the safety profile and preliminary activity of Tb-DOTAGA.Glu.(FAPi)) in patients with FAP-expressing metastatic solid tumors with an initial focus on ovarian and pancreatic cancers and sarcomas, aligning closely with Telix's own development plans for TLX400-Tx (Lu-DOTAGA.Glu.(FAPi)).